FDA approves Eli Lilly's Foundayo, the first small-molecule GLP-1 pill for obesity. GLP-1 drugs show heart and kidney benefits in Type 1 diabetes.
10 stories · Covering regulatory, research, clinical-trials, industry
The FDA approved Eli Lilly's Foundayo (orforglipron) — the first small-molecule GLP-1 pill for obesity — marking a watershed moment for oral weight-loss therapeutics. Foundayo can be taken any time of day without food or water restrictions, a significant convenience advantage over Novo Nordisk's oral Wegovy (semaglutide). In parallel, the peptide regulatory landscape continued to evolve rapidly: India's drug regulator tightened oversight on GLP-1 misuse for weight loss, while new research showed GLP-1 drugs deliver meaningful cardiovascular and kidney benefits for Type 1 diabetes patients. Meanwhile, major pharmacist conferences highlighted how GLP-1 therapies are "rewriting the rules" of metabolic disease treatment.
The FDA approved Foundayo, a once-daily oral GLP-1 pill that can be taken any time without food or water restrictions. In trials, patients lost an average of 11% body weight over one year. It was approved under the FDA's National Priority Voucher program.
A study of ~175,000 Type 1 diabetes patients found GLP-1 receptor agonists reduced five-year cardiovascular event risk by 15% and end-stage kidney disease by 19%, with no increase in severe hypoglycemia. Published in Nature Medicine.
India's Central Drugs Standard Control Organization issued advisories against unsupervised use of semaglutide and tirzepatide for weight loss, cracking down on misleading social media promotions and unapproved compounded versions.
The ATTAIN-MAINTAIN trial demonstrated that patients switching from injectable semaglutide or tirzepatide to oral orforglipron maintained their weight loss.
At APhA2026, semaglutide's FLOW trial showed 24% reduction in major kidney events in CKD patients, while tirzepatide's SURMOUNT-OSA trial demonstrated dramatic reductions in sleep apnea severity.
Foundayo's small-molecule design is easier to manufacture with fewer dosing restrictions than Novo Nordisk's peptide-based oral Wegovy. Analysts project Lilly's combined franchise could exceed $100 billion in peak revenue.
Hims & Hers Health stock rose on reports the FDA is preparing to allow compounding pharmacies to produce previously banned injectable peptides, potentially expanding the telehealth company's operations.
Federal regulators are moving toward restoring legal access to injectable peptides barred from pharmacy compounding in 2023, which could redirect patients from unregulated online sellers to regulated pharmacy channels.
A research review characterizes TB-500 and BPC-157 as distinct informational modulators, with TB-500 linked to thymosin beta-4 biology and BPC-157 acting as a localized signaling stabilizer.
STAT's pharmaceutical roundup covers the FDA's expected move to allow compounding of previously banned peptides and the impact of the Iran conflict on global clinical trial recruitment.